A Phase 3 interventional study of Imatinib mesylate and Hydroxyurea in Glioblastoma Multiforme and Astrocytoma, sponsored by Novartis Pharmaceuticals. Completed at 1 site in Germany. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2011-04-26.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing imatinib in Glioblastoma — none open to participants now, none under way, none of them phase 3. imatinib · Glioblastoma.
Among the 10 studies testing imatinib in Glioblastoma, this one has the largest enrollment, is one of 3 that started in 2004, is the only one in phase 3, and was the 3rd registered.
2,135 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.
Browse Glioblastoma studies →None of the 10 studies testing imatinib in Glioblastoma is open now. The open studies under Glioblastoma, anywhere →
imatinib: first FDA approval 2001 (GLEEVEC), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →
Of the 338 Glioblastoma studies recruiting now, 233 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 13 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 6 · Phase 3 1
First in 2001; this study’s year is marked. 3 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 240 is above the median of 36 across 1,756 interventional studies indexed under Glioblastoma.
Median enrollment 65 across the 10 interventional studies. Of the 10 that completed or were terminated, 4 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 10 have an industry lead sponsor. The 6 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
22 studies in Glioblastoma by Novartis: none open now, 4 under way, none of them phase 3. Of 18 finished, 8 (44%) have results posted.
Among the 22 studies in Glioblastoma by Novartis, this one has the largest enrollment, is one of 3 that started in 2004, is the only one in phase 3, and was the 4th registered.
Novartis’s Glioblastoma studies by the year they started, since 1998.
None of the studies under way reaches primary completion within a year.
Among the 10 studies testing imatinib in Glioblastoma, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 22 in Glioblastoma:
This tab as a report to print or save as PDF → With an account.
This is a Phase III study comparing Imatinib mesylate and hydroxyurea combination therapy with hydroxyurea monotherapy in patients with temozolomide resistant progressive glioblastoma.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-specific inclusion /exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Imatinib was supplied as 100 mg and 400 mg tablets. Patients in the combination arm were instructed to take a daily oral imatinib dose of 600 mg (600 mg at lunch time) and a daily oral hydroxyurea (HU) dose of 1000 mg (500 mg twice daily; in the morning and at bed time). Every 6 weeks after randomization based on assessment of therapeutic response, either patients continued with above mentioned dosing regimen or switched to receive a daily dose of 800 mg imatinib with 1000 mg HU. Patients were instructed to split the intake, taking 400 mg imatinib with 500 mg HU in the morning, then the same in the evening.
Drug: Imatinib mesylate · Drug: Hydroxyurea
1500 mg/day of HU given as 500 mg 3 times daily. Every 6 weeks after randomization and based on assessment of therapeutic response, the patients were either switched to combination arm or continued in monotherapy arm of hydroxyurea.
Drug: Hydroxyurea
Imatinib was supplied as 100 mg and 400 mg tablets packaged in polyethylene bottles.
Also known as: Glivec®
Also known as: Litalir®
Percentage of Participants With Progression Free Survival (PFS) During the Study Duration
PFS was defined as the time from the date of randomization to the date of the first documented progression according to the MacDonald criteria, or death due to any cause. MacDonald criteria are standard criteria in neurooncology. Tumor assessment was made according to the adapted MacDonald criteria based on the combined evaluation of 1) assessment of the MRI scan for measurable, evaluable, and new lesions (made by the independent external expert too), 2) overall assessment of neurological performance (made by the investigator), 3) concomitant steroid use (as reported by the investigator).
Time frame: 6 months -1 year
Number of Participants With Death, Other Serious or Clinically Significant Adverse Events (AEs) or Related Discontinuations
National Cancer Institute (NCI)/ National Institute of Health (NIH) provides a grading (severity) scale for each AE term. Grade 3 refers to severe AE and Grade 4 refers to life-threatening or disabling AE. According to FDA 21CFR 314.80, a serious adverse event (SAE) is described as any adverse event that leads to death, is life threatening ( NIH criteria Grade 4), causes or prolongs hospitalization, results in a congenital anomaly, or any other important medical event not described above.
Time frame: 6 months - 1 year
| Milestone | Imatinib Mesylate + Hydroxyurea (HU) | Hydroxyurea Alone |
|---|---|---|
| Started | 120 | 120 |
| Discontinued study treatment | 111 | 104 |
| Not exposed to study treatment | 2 | 2 |
| Completed | 7 | 14 |
| Not completed | 113 | 106 |
| Withdrew: Unsatisfactory therapeutic effect | 25 | 26 |
| Withdrew: Adverse event | 18 | 20 |
| Withdrew: Withdrawal by subject | 14 | 10 |
| Withdrew: Death | 5 | 13 |
| Withdrew: Study drug no longer required | 5 | 3 |
| Withdrew: Lost to follow-up | 2 | 1 |
| Withdrew: Abnormal laboratory value(s) | 0 | 2 |
| Withdrew: Protocol violation | 0 | 1 |
| Withdrew: Suspected progression of disease | 44 | 30 |
PFS was defined as the time from the date of randomization to the date of the first documented progression according to the MacDonald criteria, or death due to any cause. MacDonald criteria are standard criteria in neurooncology. Tumor assessment was made according to the adapted MacDonald criteria based on the combined evaluation of 1) assessment of the MRI scan for measurable, evaluable, and new lesions (made by the independent external expert too), 2) overall assessment of neurological performance (made by the investigator), 3) concomitant steroid use (as reported by the investigator).
| Percentage of Participants | Imatinib Mesylate + Hydroxyurea (HU) | Hydroxyurea Alone |
|---|---|---|
| 6 months | 5.3 (1.0 to 9.7) | 6.6 (2.1 to 11.1) |
| 12 months | 2.1 (0.0 to 5.0) | 2.1 (0.0 to 5.5) |
National Cancer Institute (NCI)/ National Institute of Health (NIH) provides a grading (severity) scale for each AE term. Grade 3 refers to severe AE and Grade 4 refers to life-threatening or disabling AE. According to FDA 21CFR 314.80, a serious adverse event (SAE) is described as any adverse event that leads to death, is life threatening ( NIH criteria Grade 4), causes or prolongs hospitalization, results in a congenital anomaly, or any other important medical event not described above.
| Participants | Imatinib Mesylate + Hydroxyurea (HU) | Hydroxyurea Alone |
|---|---|---|
| Deaths | 84 | 91 |
| Death due to disease progression | 76 | 77 |
| Serious Adverse Events (SAEs) | 64 | 79 |
| NCI/NIH Grade 3 (severe) or 4 (life threatening) | 54 | 64 |
| Suspected to be drug-related | 12 | 12 |
| Leading to dose adjustment or interruption | 6 | 16 |
| Leading to permanent discontinuation | 9 | 13 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Imatinib Mesylate + Hydroxyurea (HU) | — | 64/118 (54.2%) | 104/118 (88.1%) |
| Period With Hydroxyurea Alone | — | 46/118 (39%) | 80/118 (67.8%) |
| Period After Switch to Combination | — | 49/85 (57.6%) | 65/85 (76.5%) |
| Event | Imatinib Mesylate + Hydroxyurea (HU) | Period With Hydroxyurea Alone | Period After Switch to Combination |
|---|---|---|---|
| EPILEPSYNervous system disorders | 5/118 | 9/118 | 9/85 |
| PNEUMONIAInfections and infestations | 9/118 | 4/118 | 5/85 |
| HEMIPARESISNervous system disorders | 8/118 | 5/118 | 2/85 |
| GENERAL PHYSICAL HEALTH DETERIORATIONGeneral disorders | 7/118 | 6/118 | 2/85 |
| LEUKOPENIABlood and lymphatic system disorders | 1/118 | 2/118 | 5/85 |
| CONVULSIONNervous system disorders | 3/118 | 4/118 | 4/85 |
| INTRACRANIAL PRESSURE INCREASEDNervous system disorders | 3/118 | 3/118 | 4/85 |
| PARTIAL SEIZURESNervous system disorders | 1/118 | 2/118 | 4/85 |
| HEADACHENervous system disorders | 2/118 | 5/118 | 3/85 |
| FALLInjury, poisoning and procedural complications | 3/118 | 1/118 | 3/85 |
| Event | Imatinib Mesylate + Hydroxyurea (HU) | Period With Hydroxyurea Alone | Period After Switch to Combination |
|---|---|---|---|
| FATIGUEGeneral disorders | 34/118 | 16/118 | 18/85 |
| OEDEMA PERIPHERALGeneral disorders | 29/118 | 12/118 | 14/85 |
| NAUSEAGastrointestinal disorders | 28/118 | 17/118 | 10/85 |
| HEADACHENervous system disorders | 26/118 | 24/118 | 16/85 |
| THROMBOCYTOPENIABlood and lymphatic system disorders | 24/118 | 15/118 | 17/85 |
| VOMITINGGastrointestinal disorders | 21/118 | 13/118 | 6/85 |
| LEUKOPENIABlood and lymphatic system disorders | 16/118 | 14/118 | 14/85 |
| ANAEMIABlood and lymphatic system disorders | 13/118 | 8/118 | 13/85 |
| DIZZINESSNervous system disorders | 16/118 | 3/118 | 7/85 |
| HYPOKALAEMIAMetabolism and nutrition disorders | 14/118 | 2/118 | 6/85 |
| Age Continuous(years) | Imatinib Mesylate + Hydroxyurea (HU) | Hydroxyurea Alone | Total |
|---|---|---|---|
| Mean | 52.1 ± 11.3 | 50.2 ± 11.4 | 51.2 ± 11.4 |
| Sex: Female, Male(Participants) | Imatinib Mesylate + Hydroxyurea (HU) | Hydroxyurea Alone | Total |
|---|---|---|---|
| Female | 50 | 38 | 88 |
| Male | 70 | 82 | 152 |
The record gives a start of Oct 2004 and a primary completion of Aug 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2011, 2 years 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Imatinib